

Neuropeptide Y (13-36), amide, human

Cat. No.:	HY-P1480
CAS No.:	122341-40-6
Molecular Formula:	C ₁₃₄ H ₂₀₇ N ₄₁ O ₃₆ S
Molecular Weight:	3000.4
Sequence:	Pro-Ala-Glu-Asp-Met-Ala-Arg-Tyr-Tyr-Ser-Ala-Leu-Arg-His-Tyr-Ile-Asn-Leu-Ile-Thr-Arg-Gln-Arg-Tyr-NH ₂
Sequence Shortening:	PAEDMARYYSALRHYINLITRQRY-NH ₂
Target:	Neuropeptide Y Receptor
Pathway:	GPCR/G Protein; Neuronal Signaling
Storage:	Sealed storage, away from moisture and light, under nitrogen Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen)

BIOLOGICAL ACTIVITY

Description	Neuropeptide Y (13-36), amide, human is a selective neuropeptide Y ₂ receptor agonist ^[1] .								
IC₅₀ & Target	NPY Y ₂ receptor								
In Vivo	<p>Neuropeptide Y (13-36) (intraventricular injection; 25-3000 pmol) produces a dose-dependent increase (up to 14%; ED₅₀ value of 0.3 nmol for overall effects and 0.97 nmol for the peak effects) in mean arterial blood pressure in the awake, unrestrained male rat without affecting heart rate. Central administration of porcine Neuropeptide Y (13-36) produces marked vasodepressor and bradycardic actions in the anaesthetized α-chloralose and in the awake unrestrained male rat^[1]. Neuropeptide Y (13-36) (intracerebroventricular injection; 50 ng; alone; injected 30 and 15 min before measurements) injected into naïve mice impairs social novelty preference, but not sociability, and this effect is inhibited by the NPY Y₂ receptor antagonist BIIE 0246^[2].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>Male ICR mice (age 4-7 weeks)^[2]</td> </tr> <tr> <td>Dosage:</td> <td>50 ng/mouse</td> </tr> <tr> <td>Administration:</td> <td>Intracerebroventricular injection</td> </tr> <tr> <td>Result:</td> <td>Significantly decreased interaction time with the new stranger mouse in session 3 that NPY 13-36.</td> </tr> </table>	Animal Model:	Male ICR mice (age 4-7 weeks) ^[2]	Dosage:	50 ng/mouse	Administration:	Intracerebroventricular injection	Result:	Significantly decreased interaction time with the new stranger mouse in session 3 that NPY 13-36.
Animal Model:	Male ICR mice (age 4-7 weeks) ^[2]								
Dosage:	50 ng/mouse								
Administration:	Intracerebroventricular injection								
Result:	Significantly decreased interaction time with the new stranger mouse in session 3 that NPY 13-36.								

REFERENCES

[1]. Aguirre JA, et al. Centrally injected neuropeptide Y (13-36) produces vasopressor effects and antagonizes the vasodepressor action of neuropeptide Y (1-36) in the awake male rat. *Neurosci Lett.* 1990 Oct 2;118(1):5-8.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA